Know Cancer

forgot password

Phase I/II Study of SIR-Spheres Plus Sorafenib as First Line Treatment in Patients With Non-Resectable Primary Hepatocellular Carcinoma

Phase 1/Phase 2
18 Years
Open (Enrolling)
Hepatocellular Carcinoma

Thank you

Trial Information

Phase I/II Study of SIR-Spheres Plus Sorafenib as First Line Treatment in Patients With Non-Resectable Primary Hepatocellular Carcinoma

Inclusion Criteria:

- Unresectable HCC with or without systemic metastases.

- Willing, able and mentally competent to provide written informed consent prior to any
testing under this study protocol, including screening tests and evaluations that are
not considered to be part of the subject's routine care.

- Aged 18 years or older of either gender and any race, religion or socioeconomic

- Unequivocal diagnosis of primary HCC (as defined above)

- HCC that is not amenable to surgical resection or immediate liver transplantation, or
that is not optimally treatable with local ablative techniques such as
radio-frequency ablation, consistent with the practice of the clinical trial centre.

- Measurable disease, defined as at least one lesion that can be accurately measured in
at least one dimension (longest diameter to be recorded) as ≥10 mm with spiral CT

- ECOG performance status 0 - 1.

- Adequate haematological, renal and hepatic function as follows:

- Leukocytes ≥ 2,500/μL

- Absolute Neutrophil Count ≥ 1,500/μL

- Platelets ≥ 50,000/μL

- Haemoglobin > 9.5 g/dL

- Total bilirubin ≤ 2.0 mg/dL (SIR-Spheres should not be administered as a whole liver
treatment if the total bilirubin is > 2X the institutional upper limit of normal).

- INR ≤ 2.0

- ALP ≤ 5 x institutional upper limit of normal

- AST / ALT ≤ 5 x institutional upper limit of normal

- Albumin ≥ 2.5 g/dL

- Creatinine ≤ 2.0 mg/dL

- The blood results must be less than 29 days old at the time of confirming patient
eligibility to receive protocol treatment.

- Life expectancy of at least 3 months without any active treatment. This is defined as
a patient who has OKUDA I or II inoperable HCC.

- Suitable for protocol treatment as determined by clinical assessment undertaken by
the Investigator.

- Female patients must be either postmenopausal or, if premenopausal, must have a
negative pregnancy test and agree to use two forms of contraception if sexually
active during their study participation.

- Male patients must be surgically sterile, or if sexually active and having a
pre-menopausal female partner then must be using an acceptable form of contraception.

- Hepatic arterial anatomy suitable for implantation of SIR-Spheres, as assessed by
hepatic angiogram.

- Lung shunt fraction less than or equal to 20% as assessed by a Tc-99m macroaggregated
albumin liver to lung breakthrough scan.

Exclusion Criteria:

- Had previous external beam radiation therapy to the liver.

- Any ascites or other clinical signs of liver failure, on physical examination.

- Abnormal synthetic and excretory liver function tests (LFTs) as determined by serum
albumin (must be < 2.5 g/dL) and total bilirubin (must be > 2.0 mg/dL), respectively.

- Tumours amenable to surgical resection for cure at presentation.

- Greater than 20% lung shunting of the hepatic artery blood flow determined by Tc-99
MAA scan.

- Pre-assessment angiogram and Tc-99 MAA scan that demonstrates significant and
uncorrectable activity in the stomach, pancreas or bowel.

- Been treated with Capecitabine within the previous 8 weeks, or who will be treated
with Capecitabine within 8 weeks of treatment with SIR-Spheres, due to the possible
risk of potentiating or causing liver dysfunction.

- Complete main portal vein thrombosis.

- Subjects who have had hepatic artery directed therapy.

- Subjects who have had prior chemotherapy or other medical agents used to treat
hepatocellular carcinoma.

- Prior external hepatic radiation therapy for HCC, or any other concomitant therapy
for HCC or any investigational agent planned while on this protocol.

- Subjects with inferior vena cava (IVC) tumour thrombus or invasion

- Currently receiving any other investigational agents for the treatment of their

- Any other concurrent malignancy, except for adequately treated basal cell or squamous
cell skin cancer, in situ cervical cancer, or other cancer for which the patient has
been disease-free for at least five years.

- Presence of clinical signs of CNS metastases due to their poor prognosis and because
progressive neurologic dysfunction would confound the evaluation of neurologic and
other adverse events.

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection (except viral hepatitis), symptomatic congestive heart failure, unstable
angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that
would limit compliance with study requirements.

- Any of the following contraindications to angiography and selective visceral

- Bleeding diathesis, not correctable by the standard forms of therapy.

- Severe peripheral vascular disease that would preclude arterial catheterization.

- Portal hypertension with hepatofugal flow as documented on baseline spiral CT

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to SIR-Spheres.

- Inability or unwillingness to understand or sign a written informed consent document
(non English-speaking patients may use an interpreter).

- Female subjects who are pregnant or currently breastfeeding.

- For female subjects, unless postmenopausal or surgically sterile, unwillingness to
practice effective contraception, as defined by the Investigator, during the study.
The rhythm method is not to be used as the sole method of contraception.

- For male subjects, unwillingness to practice effective contraception (as defined by
the Investigator) while taking part in this study, because the effect of the
SIR-Spheres treatment on sperm or upon the development of an unborn child are

- Current enrolment in any other investigational drug or device study.

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Toxicity and safety

Outcome Time Frame:

2 years

Safety Issue:


Principal Investigator

Pierce Chow, Phd

Investigator Role:

Study Chair

Investigator Affiliation:



Singapore: Health Sciences Authority

Study ID:




Start Date:

June 2008

Completion Date:

June 2010

Related Keywords:

  • Hepatocellular Carcinoma
  • First line treatment for Hepatocellular Carcinoma
  • Carcinoma
  • Carcinoma, Hepatocellular